Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 25 October 2022, 18:00 HKT/SGT

Source: Novotech Health Holdings Pte Ltd
Clinical Research Opportunities in China and the Path to USFDA Approval - Whitepaper

SYDNEY, AU, Oct 25, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO, and GlobalData have published the latest China biotech landscape analysis with expert guidance on pathways to USFDA approval for biotechs conducting research in China.

Download whitepaper here

The report was prepared for international biotechs considering China for their clinical research, as well as China biotechs conducting research in China, and the relevant processes required for USFDA approvals.

Novotech's Vice President, Global Head of Clinical Services Dr. Yooni Kim said: "China presents exceptional clinical opportunities with vast populations and word-class research facilities and KOLs. This concise analysis of the pathway to USFDA approval expertly informs clinical stage biotechs about the China research benefits and how to manage any challenges. The report details the regulatory requirements for biotechs including NDA and IND processes as well as ex-US research guidance for a successful USFDA approval pathway. Novotech, with experienced clinical teams in China and the US, can provide the relevant regulatory knowledge and drug development pathways specifically designed to support the USFDA approval process, avoiding delays and additional costs."

The key learnings from the report are:

- Companies should engage with the USFDA early and formally to confirm guidance on their clinical roadmap.

- China's clinical development regulations are aligned with the USFDA regulations and present significant benefits for biopharma companies.

- Biopharma companies should take advantage of China's revised regulatory framework around acceptance of foreign clinical trials data for drug approval, making it easier for foreign companies to enter the Chinese market.

- For biopharma companies looking to enter China, China's pharmaceutical market has advantages such as conducting first-in-human trials (FIH) and utilization of overseas clinical trial data for clinical trial application (CTA) filing, leveraging expedited clinical development pathways for accelerating the approval process; implementation of the Marketing Authorization Holder (MAH) system, favorable government policies to enhance domestic and global innovation encourages foreign direct investments (FDIs) in R&D that benefit the overseas companies.

- Chinese biotech companies can enter developed markets in the US and Europe through strategic partnerships or by setting-up their own operations in these markets.

Novotech has operations across the Asia Pacific and the US offering a unique and unparalleled suite of CRO services for early to late-phase biotech clinical research. The company has decades of biotech drug development experience, exceptional site and investigator relationships, access to vast patient populations, and a project management approach focused on problem-solving, ownership, and flexibility. Consistent investment in advanced training and technology systems combine to deliver a specialist full-service biotech CRO solution.

Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions which delivers exclusive benefits for sponsors.

About Novotech

Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit

Media Contact
David James
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427

Topic: Press release summary
Source: Novotech Health Holdings Pte Ltd

Sectors: BioTech, Healthcare & Pharm, Clinical Trials
From the Asia Corporate News Network

Copyright © 2023 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Novotech Health Holdings Pte Ltd
Feb 15, 2023 09:00 HKT/SGT
The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar
Feb 10, 2023 19:00 HKT/SGT
Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific
Feb 3, 2023 13:00 HKT/SGT
Asia Pacific Cell & Gene Research Growing 50% Faster than ROW
Jan 12, 2023 15:00 HKT/SGT
Novotech Acquires European CRO, Strengthens Global Operations
Jan 12, 2023 15:00 HKT/SGT
Novotech Acquires US-based Drug Development Consulting Firm, CBR International
Dec 20, 2022 11:00 HKT/SGT
Novotech is Gold Sponsor at Biotech Showcase 2023
Dec 15, 2022 10:00 HKT/SGT
Data Shows 50% of New Trials Have Sites in Asia Pacific
Dec 6, 2022 11:00 HKT/SGT
Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials
Nov 11, 2022 17:00 HKT/SGT
Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy
Oct 17, 2022 11:00 HKT/SGT
The Biotech Landscape Webinar: Market Trends, Priorities, Predictions, and Pathways to FDA Approval
More news >>
 News Alerts
Copyright © 2023 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: